Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
The global Tyrosine Kinase JAK Inhibitors market size was valued at US$ 48580 million in 2023 and is forecast to a readjusted size of USD 786610 million by 2030 with a CAGR of 49.4% during review period.
The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.
North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
麻豆原创 competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42% market sharers.
This report is a detailed and comprehensive analysis for global Tyrosine Kinase JAK Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Tyrosine Kinase JAK Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Tyrosine Kinase JAK Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Tyrosine Kinase JAK Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Tyrosine Kinase JAK Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tyrosine Kinase JAK Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tyrosine Kinase JAK Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie, Vertex, Teva, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Tyrosine Kinase JAK Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Tofacitinib
Ruxolitinib
Baricitinib
麻豆原创 segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
Major players covered
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tyrosine Kinase JAK Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tyrosine Kinase JAK Inhibitors, with price, sales quantity, revenue, and global market share of Tyrosine Kinase JAK Inhibitors from 2019 to 2024.
Chapter 3, the Tyrosine Kinase JAK Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tyrosine Kinase JAK Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Tyrosine Kinase JAK Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tyrosine Kinase JAK Inhibitors.
Chapter 14 and 15, to describe Tyrosine Kinase JAK Inhibitors sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Tofacitinib
1.3.3 Ruxolitinib
1.3.4 Baricitinib
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Rheumatoid Arthritis (RA)
1.4.3 Polycythemia Vera (PCV)
1.4.4 Myelofibrosis (MF)
1.4.5 Others
1.5 Global Tyrosine Kinase JAK Inhibitors 麻豆原创 Size & Forecast
1.5.1 Global Tyrosine Kinase JAK Inhibitors Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Tyrosine Kinase JAK Inhibitors Sales Quantity (2019-2030)
1.5.3 Global Tyrosine Kinase JAK Inhibitors Average Price (2019-2030)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Product and Services
2.1.4 Pfizer Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Pfizer Recent Developments/Updates
2.2 Incyte
2.2.1 Incyte Details
2.2.2 Incyte Major Business
2.2.3 Incyte Tyrosine Kinase JAK Inhibitors Product and Services
2.2.4 Incyte Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Incyte Recent Developments/Updates
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Tyrosine Kinase JAK Inhibitors Product and Services
2.3.4 Novartis Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Novartis Recent Developments/Updates
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business
2.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Product and Services
2.4.4 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Eli Lilly Recent Developments/Updates
2.5 Gilead
2.5.1 Gilead Details
2.5.2 Gilead Major Business
2.5.3 Gilead Tyrosine Kinase JAK Inhibitors Product and Services
2.5.4 Gilead Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Gilead Recent Developments/Updates
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Product and Services
2.6.4 Sanofi Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Sanofi Recent Developments/Updates
2.7 Galapagos
2.7.1 Galapagos Details
2.7.2 Galapagos Major Business
2.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Product and Services
2.7.4 Galapagos Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Galapagos Recent Developments/Updates
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Product and Services
2.8.4 AbbVie Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 AbbVie Recent Developments/Updates
2.9 Vertex
2.9.1 Vertex Details
2.9.2 Vertex Major Business
2.9.3 Vertex Tyrosine Kinase JAK Inhibitors Product and Services
2.9.4 Vertex Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Vertex Recent Developments/Updates
2.10 Teva
2.10.1 Teva Details
2.10.2 Teva Major Business
2.10.3 Teva Tyrosine Kinase JAK Inhibitors Product and Services
2.10.4 Teva Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Teva Recent Developments/Updates
2.11 Astellas Pharma
2.11.1 Astellas Pharma Details
2.11.2 Astellas Pharma Major Business
2.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product and Services
2.11.4 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Astellas Pharma Recent Developments/Updates
2.12 Celgene
2.12.1 Celgene Details
2.12.2 Celgene Major Business
2.12.3 Celgene Tyrosine Kinase JAK Inhibitors Product and Services
2.12.4 Celgene Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Celgene Recent Developments/Updates
2.13 CTI BioPharma
2.13.1 CTI BioPharma Details
2.13.2 CTI BioPharma Major Business
2.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product and Services
2.13.4 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 CTI BioPharma Recent Developments/Updates
3 Competitive Environment: Tyrosine Kinase JAK Inhibitors by Manufacturer
3.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Manufacturer (2019-2024)
3.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Manufacturer (2019-2024)
3.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of Tyrosine Kinase JAK Inhibitors by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 Tyrosine Kinase JAK Inhibitors Manufacturer 麻豆原创 Share in 2023
3.4.3 Top 6 Tyrosine Kinase JAK Inhibitors Manufacturer 麻豆原创 Share in 2023
3.5 Tyrosine Kinase JAK Inhibitors 麻豆原创: Overall Company Footprint Analysis
3.5.1 Tyrosine Kinase JAK Inhibitors 麻豆原创: Region Footprint
3.5.2 Tyrosine Kinase JAK Inhibitors 麻豆原创: Company Product Type Footprint
3.5.3 Tyrosine Kinase JAK Inhibitors 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Tyrosine Kinase JAK Inhibitors 麻豆原创 Size by Region
4.1.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2019-2030)
4.1.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2019-2030)
4.1.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2019-2030)
4.2 North America Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.3 Europe Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.4 Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.5 South America Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.6 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
5.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type (2019-2030)
5.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
6.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application (2019-2030)
6.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2019-2030)
7 North America
7.1 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
7.2 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
7.3 North America Tyrosine Kinase JAK Inhibitors 麻豆原创 Size by Country
7.3.1 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
7.3.2 North America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
8.2 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
8.3 Europe Tyrosine Kinase JAK Inhibitors 麻豆原创 Size by Country
8.3.1 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
8.3.2 Europe Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Tyrosine Kinase JAK Inhibitors 麻豆原创 Size by Region
9.3.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 South Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
10.2 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
10.3 South America Tyrosine Kinase JAK Inhibitors 麻豆原创 Size by Country
10.3.1 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
10.3.2 South America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Tyrosine Kinase JAK Inhibitors 麻豆原创 Size by Country
11.3.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 Tyrosine Kinase JAK Inhibitors 麻豆原创 Drivers
12.2 Tyrosine Kinase JAK Inhibitors 麻豆原创 Restraints
12.3 Tyrosine Kinase JAK Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Tyrosine Kinase JAK Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of Tyrosine Kinase JAK Inhibitors
13.3 Tyrosine Kinase JAK Inhibitors Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Tyrosine Kinase JAK Inhibitors Typical Distributors
14.3 Tyrosine Kinase JAK Inhibitors Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
听
听
*If Applicable.
